Valion Bio披露Entolimod政府沟通、200倍放大生产和肿瘤支持治疗扩展进展

Strategic execution across multiple initiatives positions the Entolimod platform to pursue opportunities in government preparedness, domestic biomanufacturing and oncology supportive care
SAN ANTONIO, July 14, 2026 /PRNewswire/ -- Valion Bio, Inc. (Nasdaq: VBIO) ("Valion Bio" or the "Company") is pleased to report across a series of strategic initiatives for its Entolimod program — including continued engagement with U.S. government agencies and allied nations on Acute Radiation Syndrome (ARS) preparedness, a demonstrated 200-fold manufacturing scale-up through its wholly owned subsidiary Velocity Bioworks®, and planned expansion into innovative oncology supportive care.
These developments reflect the Company's evolution from a single product candidate into an integrated biotechnology platform. Taken together, these initiatives have significantly strengthened the Company's ability to pursue multiple avenues of near-, mid- and long-term value creation.
What Happened
During the past weeks, Valion Bio has:
- Continued engagement with the Biomedical Advanced Research and Development Authority, or BARDA, the National Institute of Allergy and Infectious Diseases, or NIAID, the Armed Forces Radiobiology Research Institute, or AFRRI, and the U.S. Department of War, or DoW, regarding potential development support and Strategic National Stockpile opportunities for Entolimod.
- Continued discussions with Ukraine's Ministry of Health following its previously disclosed Request for Information regarding the potential evaluation of Entolimod for inclusion in Ukraine's national strategic reserves.
- Demonstrated an approximately 200-fold manufacturing scale-up of Entolimod through the Company's wholly owned contract development and manufacturing organization, Velocity Bioworks®, at the 50-liter fermentation scale — equivalent to approximately 1.3 million potential human doses, based on the Company's current estimates — while meeting applicable purity and potency specifications.
- Advanced preparations to evaluate Entolimod in oncology supportive care, beginning with planned physician-sponsored studies in neutropenia.
- Continued development of Entolasta, the Company's next-generation TLR5 agonist, for potential use in oncology supportive care and other immunomodulatory applications.
Why It Matters
These developments support Valion Bio's broader strategy to build an integrated biotechnology platform around a common scientific and manufacturing foundation:
- Government preparedness: Entolimod is being advanced as a potential medical countermeasure for Acute Radiation Syndrome, or ARS, under the U.S. Food and Drug Administration's Animal Rule and has received FDA Fast Track and Orphan Drug designations.
- Domestic manufacturing: Ownership of Velocity Bioworks provides Valion Bio with greater control over process development, production timing and supply-chain readiness while creating the potential to support future government procurement, internal development programs and third-party CDMO services.
- Oncology expansion: The biological activity of the TLR5 platform may support development opportunities beyond biodefense, including oncology supportive care.
- Multiple potential value drivers: Valion Bio's strategy is designed to create several potential pathways for advancement through government funding and procurement, clinical development, platform expansion and biomanufacturing.
"Over the past year, our focus has extended beyond advancing a single product candidate," said Michael K. Handley, Chief Executive Officer of Valion Bio. "We have been building the regulatory, government, clinical and manufacturing capabilities needed to support the long-term development of the Entolimod platform. Today, Valion Bio has a biodefense program advancing under the FDA Animal Rule, active engagement with U.S. and allied-government stakeholders, company-owned domestic manufacturing and a defined path toward innovating important potential applications in oncology supportive care."
Government Preparedness Remains the Lead Development Opportunity
Government preparedness represents the most advanced potential development and commercial pathway for Entolimod. The product candidate is being advanced as a medical countermeasure for ARS, a serious and potentially fatal condition resulting from exposure to high levels of ionizing radiation.
Entolimod is designed to activate TLR5 and downstream NF-κB signaling pathways associated with cell survival, tissue protection and immune response. The Company believes the product candidate's potential to address both the gastrointestinal and hematopoietic effects of radiation injury, together with its potential use before or after exposure, may differentiate it from currently available or stockpiled approaches.
Because conventional human efficacy trials cannot ethically be conducted in ARS, Entolimod is being developed under the FDA Animal Rule, which permits efficacy findings from well-controlled animal studies to support approval when human efficacy trials are not ethical or feasible, provided applicable regulatory requirements are satisfied.
Valion Bio continues to engage with BARDA, NIAID, AFRRI and the DoW regarding potential non-dilutive development support and future Strategic National Stockpile opportunities. These discussions remain ongoing, and while no funding, procurement or stockpiling agreement has been executed, Valion Bio believes these conversations have been productive and evidence a potentially strong collaboration.
The Company is also pursuing potential preparedness opportunities outside the United States. As previously announced, Valion Bio received a formal Request for Information from Ukraine's Ministry of Health regarding the evaluation of Entolimod for potential inclusion in Ukraine's national strategic reserves.
Valion Bio continues to work with the Ministry regarding a possible pre-submission meeting and potential regulatory pathway. No agreement has been executed, and there can be no assurance that these discussions will result in regulatory authorization, a stockpiling agreement, procurement or revenue.
The Company believes engagement with both U.S. agencies and allied governments reflects the urgent need for and broader interest in medical countermeasures capable of supporting national preparedness and response planning. Each jurisdiction, however, maintains its own regulatory, funding and procurement requirements, and the timing and outcome of these processes remain uncertain.
Integrated Manufacturing Supports Development and Preparedness Readiness
"Our next phase is centered on execution," Handley added. "We intend to continue advancing the Animal Rule pathway, pursue potential government-supported development and procurement opportunities, strengthen manufacturing readiness and generate additional clinical evidence that may broaden the utility of the platform."
Valion Bio's ownership of Velocity Bioworks is intended to give the Company greater control over a function central to both product development and potential government procurement. The 200-fold scale-up demonstrated through the subsidiary is significant not only as a technical achievement but as evidence of the Company's ability to establish a more scalable, domestically controlled supply chain for Entolimod — with reliable capacity, validated processes and at-scale production expected to be important considerations in any future government-supported development or procurement program.
Directly-owned manufacturing may also provide greater flexibility in production scheduling, process improvements and clinical-development coordination, potentially reducing dependence on third-party manufacturers while improving visibility into costs, timelines and supply.
Velocity Bioworks is also intended to serve third-party biotechnology companies, particularly early-stage and Phase I or Phase II biologics programs, offering a potential complementary source of revenue while